The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 April 2026•

1 min read

Haisco and AbbVie Sign Exclusive Licensing Deal for Novel Pain Management Drugs

Key Facts

1Haisco Pharmaceutical Group entered into an exclusive licensing agreement with global biopharmaceutical company AbbVie.

2The agreement aims to develop novel medicines specifically for pain management.

Version History

2 additional sources confirmed this story

Haisco Pharmaceutical Group has officially entered into an exclusive licensing agreement with global biopharmaceutical giant AbbVie to develop innovative pain management medicines. Announced on April 10, 2026, the partnership focuses on leveraging Haisco's research capabilities alongside AbbVie's extensive global development infrastructure. This collaboration aims to address unmet needs in the pain treatment market through the advancement of novel pharmaceutical candidates. For Haisco, the deal serves as a significant validation of its research and development pipeline, potentially opening doors for future milestone payments. Meanwhile, AbbVie strengthens its existing portfolio in the specialized field of pain management, enhancing its competitive position. Investors view this strategic alliance as a bullish signal for both companies, reflecting a shared commitment to clinical innovation and market expansion.